JWCAR-201

N/A

Report date: 2024/09/06 14:17:53

Base Information

Drug NameJWCAR-201
Drug Alias NameAutologous CD19/CD20-directed CAR-T cells therapy (Shanghai Ming Ju Biotechnology)JWCAR201JWCAR-201
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD19Anti-CD20T lymphocyte replacements
TargetsB-lymphocyte antigen CD19B-lymphocyte antigen CD20
Therapy Area/IndicationsAutoimmune DiseasesLupus Erythematosus, SystemicLymphoma, Large B-Cell, Diffuse +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Ming Ju Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesFudan UniversityShanghai Ming Ju Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesLupus Erythematosus, SystemicLymphoma, Large B-Cell, Diffuse +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A